Our core R&D facility, based in Plymouth, MI, is comprised of some of the best scientific minds in academia and research.

Luke Peterson, Ph.D.


Dr. Peterson has nearly 30 years of scientific research expertise and has participated in ground-breaking clinical oncology research. He was one of the team members to discover an alternative splice variant associated with the t(8;21) translocation that promotes acute myeloid leukemia. He was involved in early clinical development of an MDM2 inhibitor for the treatment of chronic myeloid leukemia and involved in the discovery of a deubiquitinase-inhibitor for the treatment of myeloma, melanoma and pancreatic cancer.

Miao-Chia Lo, Ph.D.


Dr. Lo has nearly three decades of oncology research experience. She was the first to discover downregulation of CD45 in t(8;21) leukemia cells, show that CD45 downregulation leads to enhanced JAK/STAT signaling in t(8;21) leukemia cells and demonstrate the therapeutic potential of JAK inhibitors in treating t(8;21) leukemia.

Scientific Advisors

Prof. David L. Van Vranken, Ph.D.

University of California, Irvine

Dr. Van Vranken is a Professor of Chemistry and Associate Dean at the University of California, Irvine with a research history spanning natural product synthesis, new transition metal catalyzed reactions, and synthesis of bioactive compounds.

Prof. Paul J. Feustel, M.Eng., Ph.D.

Albany Medical College

Dr. Feustel is the Director of the Office of Research Affairs at Albany Medical College with over 40 years of experience in biomedical research.